



Tumor Microenvironment and Anti-angiogenic Therapies

Guest Editors:

Dr. Jerome Devy

Matrice Extracellulaire et
Dynamique Cellulaire, MEDyC,
UMR 7369 CNRS-URCA, Université
de Reims Champagne-Ardenne,
51687 Reims CEDEX 2, France

Dr. Benoit Langlois

Matrice Extracellulaire et
Dynamique Cellulaire, MEDyC,
UMR 7369 CNRS-URCA, Université
de Reims Champagne-Ardenne,
51687 Reims CEDEX 2, France

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editors

Dear Colleagues,

Anti-angiogenic therapies should have revolutionized anti-tumoral strategies, but patient benefit is not the expected one. The aim of this Special Issue is to cover recent advances on the molecular and cellular mechanisms involved in tumor angiogenesis with a focus on major components of the tumor microenvironment, such as cancer associated fibroblasts, immune cells and endothelial cells progenitors and their close relation with the extracellular matrix. This special issue will also collect novel findings and reviews on the strategies aiming to control the stromal reaction of the tumor in the frame of anti-angiogenic and combinatorial treatments and the developments in the fields of tumor vessels and endothelial cell metabolism normalization that could open promising avenues to counter resistance mechanisms.

Dr. Jerome Devy
Dr. Benoit Langlois
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)